Valuation : Soleno Therapeutics, Inc.

Market Cap 2.76B 2.38B 2.24B 2.04B 3.82B 261B 3.83B 26.43B 10.26B 134B 10.37B 10.15B 431B P/E 2024
-10.3x
P/E 2025 119x
Enterprise Value 2.31B 1.99B 1.87B 1.71B 3.2B 218B 3.2B 22.09B 8.57B 112B 8.67B 8.48B 360B EV / Sales 2024
-
EV / Sales 2025 10,678,497x
Free-Float
98.88%
Yield 2024 *
-
Yield 2025 -
1 day+0.04%
6 months+37.44%
Current year+14.49%
Current year 29.43
Extreme 29.43
53.01
1 year 29.43
Extreme 29.43
72.99
3 years 3.69
Extreme 3.69
90.32
5 years 0.85
Extreme 0.85
90.32
10 years 0.85
Extreme 0.85
99
Manager TitleAgeSince
President 61 2026-05-14
Treasurer 46 2026-05-14
Director TitleAgeSince
Director/Board Member 61 2026-05-14
Director/Board Member 46 2026-05-14
Date Insider Type Main position Quantity % Market Cap. Importance
5/18/26 Issuer sale

Director

-16,991 0.0329%
5/18/26 Issuer sale

SEE REMARKS

-150,284 0.2911%
5/18/26 Issuer sale

Director

-19,554 0.0379%
Change 5-day change 1-year change 3-year change Capi.($)
+0.04%-.--%-24.02%+1,162.14% 2.76B
-1.79%-2.27%+43.23%+88.96% 67.98B
-2.06%-0.18%+39.67%+86.44% 64.94B
-0.31%+6.54%-12.96%+378.92% 27.58B
+0.86%+1.65%-7.74%-14.95% 26.06B
-3.00%-2.90%+33.13%+12.54% 25.74B
-1.46%+0.42%+23.61%-18.61% 20.09B
-2.96%-15.21%+216.20%+368.10% 17.16B
-1.49%-4.88%-6.60%+531.89% 14.92B
-0.20%+8.37%+55.78%+164.98% 14.62B
Average -1.24%+0.24%+36.03%+276.04% 28.19B
Weighted average by Cap. -1.50%+0.18%+37.76%+147.39%

Financials

2024 2025
Net sales - 190.4 163.84 154.15 140.82 263.43 17.98K 264.15 1.82K 706.86 9.22K 714.99 699.4 29.71K
Net income -176M -151M -142M -130M -243M -16.6B -244M -1.68B -653M -8.52B -660M -646M -27.44B 20.89M 17.98M 16.91M 15.45M 28.9M 1.97B 28.98M 200M 77.55M 1.01B 78.44M 76.73M 3.26B
Net Debt -266M -229M -215M -197M -368M -25.1B -369M -2.54B -987M -12.88B -998M -976M -41.48B -454M -390M -367M -335M -627M -42.82B -629M -4.34B -1.68B -21.97B -1.7B -1.67B -70.78B
Logo Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The KATP channels play a central role in the regulation of a number of physiological processes which may otherwise be dysregulated, contributing to the pathophysiology of several diseases. In the context of the underlying genetic or structural defects in PWS, these pathophysiological processes may cumulatively contribute to increases in appetite and aggressive food seeking, lack of satiety, accumulation of excess body fat and the establishment and perpetuation of the obese state. PWS is a rare, complex genetic neurobehavioral/metabolic disorder. The Company sells its product primarily to a specialty pharmacy.
Employees
182
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
  1. Stock Market
  2. Stocks
  3. SLNO Stock